The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Immunocore Holdings Pretax Margin % Related Terms
Immunocore Holdings Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Immunocore Holdings's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMCR vs MAZE, DMRA, AVBP: Pretax Margin % Comparison
For the Biotechnology subindustry, Immunocore Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunocore Holdings (IMCR) has a Pretax Margin % of 12.44% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Immunocore Holdings and its competitors. According to the industry distribution chart, Immunocore Holdings ranks #284 out of 944 companies in the Biotechnology industry, placing it in the top 30.1%.
Is Immunocore Holdings' Pretax Margin % too high?
Immunocore Holdings' current Pretax Margin % is 12.44%. Based on the distribution chart, Immunocore Holdings ranks #284 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immunocore Holdings has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Pretax Margin % compare to MAZE and DMRA?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #284 out of 944 companies for Pretax Margin %. This puts Immunocore Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Immunocore Holdings and its competitors. Immunocore Holdings's current Pretax Margin % is 12.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $46.11, compared to a current price of $30.43 — trading 34% below its estimated fair value. The current Pretax Margin % is 12.44%. Immunocore Holdings' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Pretax Margin % is 12.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $30.43 is trading 34% below its estimated GF Value™ of $46.11.
GuruFocus considers Immunocore Holdings to be Possible Value Trap.
Key valuation signals for IMCR:
Pretax Margin %: 12.44%
GF Value™: $46.11 vs. price of $30.43 (34% below fair value)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
72GF Score
Get the complete analysis for IMCR
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
